Cisen Pharmaceutical Co Ltd - Asset Resilience Ratio
Cisen Pharmaceutical Co Ltd (603367) has an Asset Resilience Ratio of 35.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cisen Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Cisen Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603367 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cisen Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cisen Pharmaceutical Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.70 Billion | 35.37% |
| Total Liquid Assets | CN¥2.70 Billion | 35.37% |
Asset Resilience Insights
- Very High Liquidity: Cisen Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 35.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cisen Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Cisen Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Cisen Pharmaceutical Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Cisen Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.88% | CN¥1.28 Billion ≈ $186.58 Million |
CN¥7.55 Billion ≈ $1.11 Billion |
-5.44pp |
| 2023-12-31 | 22.32% | CN¥1.64 Billion ≈ $239.64 Million |
CN¥7.34 Billion ≈ $1.07 Billion |
-0.42pp |
| 2022-12-31 | 22.74% | CN¥1.55 Billion ≈ $226.77 Million |
CN¥6.82 Billion ≈ $997.26 Million |
-0.59pp |
| 2021-12-31 | 23.33% | CN¥1.48 Billion ≈ $217.25 Million |
CN¥6.36 Billion ≈ $931.21 Million |
-7.08pp |
| 2020-12-31 | 30.41% | CN¥1.88 Billion ≈ $274.41 Million |
CN¥6.17 Billion ≈ $902.24 Million |
-5.30pp |
| 2019-12-31 | 35.72% | CN¥1.98 Billion ≈ $289.24 Million |
CN¥5.53 Billion ≈ $809.76 Million |
+35.45pp |
| 2018-12-31 | 0.27% | CN¥14.33 Million ≈ $2.10 Million |
CN¥5.25 Billion ≈ $768.00 Million |
-0.15pp |
| 2017-12-31 | 0.42% | CN¥20.00 Million ≈ $2.93 Million |
CN¥4.74 Billion ≈ $693.89 Million |
-3.24pp |
| 2016-12-31 | 3.66% | CN¥120.00 Million ≈ $17.56 Million |
CN¥3.28 Billion ≈ $480.08 Million |
+1.68pp |
| 2015-12-31 | 1.98% | CN¥60.00 Million ≈ $8.78 Million |
CN¥3.03 Billion ≈ $443.97 Million |
-- |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infe… Read more